Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 14,400 shares, an increase of 100.0% from the June 30th total of 7,200 shares. Based on an average daily volume of 43,900 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.2% of the company’s shares are sold short.
Synaptogenix Price Performance
Synaptogenix stock traded up $0.11 during trading on Friday, reaching $4.25. The company had a trading volume of 41,744 shares, compared to its average volume of 43,668. Synaptogenix has a 12-month low of $3.53 and a 12-month high of $20.25. The stock’s 50 day moving average price is $4.35 and its two-hundred day moving average price is $4.73.
Synaptogenix (NASDAQ:SNPX – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.41) earnings per share (EPS) for the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Synaptogenix
Synaptogenix Company Profile
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Further Reading
- Five stocks we like better than Synaptogenix
- What is a buyback in stocks? A comprehensive guide for investors
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Want to Profit on the Downtrend? Downtrends, Explained.
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- EV Stocks and How to Profit from Them
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.